Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.
Daisuke ItoSatoshi ShimizuAkifumi HaisaShinnosuke YanagisawaKazuyuki InoueDaigo SaitoTakashi SumitaMorifumi YanagisawaYoshihito UchidaKouichi InukaiAkira ShimadaPublished in: Journal of diabetes investigation (2024)
Ipragliflozin and pioglitazone improved MASLD and glycemic parameters over 5 years. In the ipragliflozin group, significant reductions in body weight and visceral fat mass persisted for 5 years.